Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion

Ann Hematol. 2014 May;93(5):893-4. doi: 10.1007/s00277-013-1889-8. Epub 2013 Aug 29.

Authors

Kazuhisa Chonabayashi¹, Shigeki Tamori, Masafumi Taniwaki, Haruyuki Fujita, Yayoi Shimazu, Yusuke Matsui, Masakatsu Hishizawa, Kazumasa Usami, Akifumi Takaori-Kondo

Affiliation

¹ Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan, kchona@kuhp.kyoto-u.ac.jp.

PMID: 23989669
DOI: 10.1007/s00277-013-1889-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use
Cyclin-Dependent Kinase Inhibitor p15 / deficiency
Cyclin-Dependent Kinase Inhibitor p15 / genetics*
Cyclin-Dependent Kinase Inhibitor p16 / deficiency
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
Drug Resistance, Neoplasm*
Fatal Outcome
Gene Deletion
Gene Expression
Humans
Immunoglobulins / genetics*
Interferon Regulatory Factors / genetics*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / genetics*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Middle Aged

Substances

Antineoplastic Agents
CDKN2B protein, human
Cyclin-Dependent Kinase Inhibitor p15
Cyclin-Dependent Kinase Inhibitor p16
IgK
Immunoglobulins
Interferon Regulatory Factors
interferon regulatory factor-4